American Society of Hirudotherapy

Cutaneous Lichen Planus (Localized)

Investigational use for localized cutaneous lichen planus refractory to topical corticosteroid; very limited case-report evidence.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for lichen planus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for lichen planus is investigational.
What evidence exists?
Tier C (investigational). Only case-report-level evidence (one multimodal Ayurvedic case with improvement, where the effect of the leeches cannot be separated, and one case of lichen planus appearing after leech therapy); no randomized controlled trial was identified. Evidence-based therapy for localized cutaneous lichen planus is potent topical corticosteroid (clobetasol 0.05 percent), topical calcineurin inhibitors (tacrolimus, pimecrolimus), and intralesional triamcinolone for hypertrophic lesions. Phototherapy (narrow-band UVB, PUVA) and systemic agents (acitretin, hydroxychloroquine, methotrexate) are used for widespread or recalcitrant disease. Oral, genital, and erosive subtypes require dermatologic specialty care.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness at the application area for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Koebner phenomenon (new lichen-planus lesions at bite sites in actively flaring disease)
  • Post-inflammatory hyperpigmentation, especially in darker Fitzpatrick skin types
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • Delay or replacement of evidence-based topical or systemic therapy
Who should not consider this
  • Patients with oral, genital, or erosive lichen planus subtypes
  • Patients with active hepatitis C co-infection without hepatology management
  • Patients with suspected lichenoid drug eruption (taper the offending medication first)
  • Patients with weeping, eroded, or actively flaring lesions
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients who have not tried first-line topical or intralesional corticosteroid
What to ask your clinician
  • Has the diagnosis been confirmed by biopsy, especially if other diagnoses are possible?
  • Have I been screened for hepatitis C (associated in some populations)?
  • Is this a drug-induced lichenoid reaction (review all medications)?
  • Have I tried potent topical corticosteroid (clobetasol) or intralesional triamcinolone?
  • If widespread, am I a candidate for phototherapy (NB-UVB) or systemic therapy?
  • What evidence supports leech therapy for lichen planus specifically?
  • What is the practitioner's experience and Aeromonas-prevention plan?
When to seek urgent care
  • Painful or rapidly enlarging mouth, throat, or genital ulcers (mucosal lichen planus — needs specialty care)
  • Difficulty swallowing or hoarseness (esophageal or laryngeal involvement)
  • Severe vulvovaginal or penile pain, scarring, or new urinary symptoms
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for lichen planus.
  • Case reports do NOT establish efficacy versus topical / intralesional corticosteroid, calcineurin inhibitors, or phototherapy.
  • Mechanism rationale does NOT establish clinical efficacy.
  • Oral, genital, and erosive lichen planus REQUIRE dermatologic specialty care — leech therapy is not appropriate.
  • Leech therapy is not a substitute for evidence-based therapy.

Clinical Profile

Category
Dermatological
ICD-10
L43.0, L43.1, L43.2, L43.3, L43.8, L43.9
Safety tier
Medium

Evidence Summary

Localized cutaneous lichen planus is conventionally treated with potent topical corticosteroid, topical calcineurin inhibitors, and intralesional steroid for hypertrophic lesions. Phototherapy and systemic agents (acitretin, hydroxychloroquine, methotrexate) are reserved for widespread or recalcitrant disease. No controlled trial of leech therapy for lichen planus was identified. The only report of leech therapy for cutaneous lichen planus found is a single multimodal Ayurvedic case study (Shah 2025: a 27-year-old woman given purgation, enema and leech therapy followed by oral medicines, with reported improvement), in which the effect of the leeches cannot be separated from the other treatments; the Baskova and Isakhanyan 2004 monograph also lists complicated oral lichen planus among Russian dental indications (Gileva 1997 and others) without patient numbers or results. Use for this indication is not supported. In fact, lichen planus is a Koebner-positive (trauma-triggered) disease, and there is a published case of lichen planus arising after hirudotherapy, meaning leech application is a reported potential trigger rather than a treatment. Oral, genital, and erosive variants require dermatologic specialty care.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • This page is about lichen planus of the skin, while the books write only about its form on the oral mucous membrane: Baskova and Isakhanyan list “complicated forms of lichen planus of the oral mucosa” among the indications for hirudotherapy in dentistry[B1].
  • In the retelling of Gileva’s review (1997), lichen planus of the oral mucosa is named among the conditions for which “a comprehensive clinical and functional rationale” for the use of leeches is presented; the text gives no numbers of patients or results for it, and the reference list includes a work titled “Hirudotherapy in the combined treatment of lichen planus of the oral mucous membrane”, the content of which is not retold in the book[B1].
  • In the section on dermatology, Baskova and Isakhanyan list skin diseases (psoriasis, systemic lupus erythematosus, scleroderma, elephantiasis, eczema, pyoderma, erysipelas, condylomata acuminata (genital warts)), but lichen planus of the skin is not among them[B1].
  • Michalsen et al. do not write about lichen planus, including of the skin.
  • In the chapter on indications and contraindications, Baskova and Isakhanyan name, among others, the following cases in which hirudotherapy is contraindicated: hemophilia, hemorrhagic diatheses, anemias, low blood pressure (hypotension), acute vascular insufficiency (shock, collapse, fainting), emaciation, concurrent prescription of anticoagulants (especially with long-term, daily use), concurrent use of alcohol, external use of large doses of mercury preparations together with leeches, individual intolerance, and an extremely negative attitude of the patient toward leeches[B1].
  • Michalsen et al. (chapter 8, Flecken and Michalsen) name hemophilia and concurrent use of anticoagulants as an absolute contraindication; in the same chapter, anemia and bone-marrow suppression, HIV infection, a known peptic ulcer or erosive gastritis, severe unstable disease of the internal organs or marked suppression of the immune system, a severe tendency to allergy, and emaciation of any cause are also listed as contraindications[B3].
  • Baskova and Isakhanyan consider hirudotherapy relatively contraindicated where leeches could lead to cosmetic defects, advise refraining from it when body temperature is high, and call its use in pregnancy an open question; Michalsen et al. write that treatment involving blood loss is generally contraindicated in pregnancy and that, in their experience, during the acute stage of an infectious disease it can cause weakness and impair wound healing, and they advise restraint on the face and other conspicuous places for esthetic reasons[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Oral, genital, or erosive lichen planus subtypes
  • Active hepatitis C co-infection without hepatology management
  • Suspected lichenoid drug eruption (taper offending agent first)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.